J. A. Fishman, Overview: Cytomegalovirus and the Herpesviruses in Transplantation: Overview: The Herpesviruses, American Journal of Transplantation, vol.13, issue.s3, pp.1-8, 2013.

M. J. Cannon, D. S. Schmid, and T. B. Hyde, Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection, Reviews in Medical Virology, vol.20, issue.4, pp.202-215, 2010.

M. Mazeron, A. S. Leruez-ville, M. Schnepf, and N. , Infections à cytomégalovirus. EMC -Maladies infectieuses, vol.6, pp.1-19, 2009.

S. Kijpittayarit, A. J. Eid, R. A. Brown, C. V. Paya, and R. R. Razonable, Relationship between Toll-Like Receptor 2 Polymorphism and Cytomegalovirus Disease after Liver Transplantation, Clinical Infectious Diseases, vol.44, issue.10, pp.1315-1335, 2007.

M. Stern, H. Elsässer, G. Hönger, J. Steiger, S. Schaub et al., The Number of Activating KIR Genes Inversely Correlates with the Rate of CMV Infection/Reactivation in Kidney Transplant Recipients, American Journal of Transplantation, vol.8, issue.6, pp.1312-1319, 2008.

S. F. Atabani, C. Smith, C. Atkinson, R. W. Aldridge, M. Rodriguez-perálvarez et al., Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients Managed by Preemptive Therapy: CMV and Preemptive Antiviral Therapy, American Journal of Transplantation, vol.12, issue.9, pp.2457-64, 2012.

J. Dechanet, P. Merville, F. Berge, G. Bone-mane, J. Taupin et al., Major Expansion of gd T Lymphocytes following Cytomegalovirus Infection in Kidney Allograft Recipients, The Journal of Infectious Disease, 1999.

H. Kaminski, I. Garrigue, L. Couzi, B. Taton, T. Bachelet et al., Surveillance of ?? T Cells Predicts Cytomegalovirus Infection Resolution in Kidney Transplants, Journal of American Society of Nephrology, vol.27, issue.2, pp.637-682, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01288893

J. A. Fishman, Infection in Solid-Organ Transplant Recipients, The New England Journal of Medicine, vol.14, 2007.

H. Kaminski, L. Couzi, I. Garrigue, J. Moreau, J. Déchanet-merville et al., Easier Control of Late-Onset Cytomegalovirus Disease Following Universal Prophylaxis Through an Early Antiviral Immune Response in Donor-Positive, Recipient-Negative Kidney Transplants, Am J Transplant, vol.16, issue.8, pp.2384-94, 2016.

A. C. Webster, L. P. Ruster, R. G. Mcgee, S. L. Matheson, G. Y. Higgins et al.,

, Interleukin 2 receptor antagonists for kidney transplant recipients, Cochrane Database of Systematic Reviews, 2010.

C. Santos, D. C. Brennan, V. J. Fraser, and M. A. Olsen, Delayed-Onset Cytomegalovirus Disease Coded During Hospital Readmission After Kidney Transplantation: Transplantation, vol.98, pp.187-94, 2014.

O. Manuel, G. Kralidis, N. J. Mueller, H. H. Hirsch, C. Garzoni et al., Impact of Antiviral Preventive Strategies on the Incidence and Outcomes of Cytomegalovirus Disease in Solid Organ Transplant Recipients: Impact of CMV Prevention, American Journal of Transplantation, vol.13, issue.9, pp.2402-2412, 2013.

L. Azevedo, L. Pierrotti, E. Abdala, S. Costa, T. Strabelli et al., Cytomegalovirus infection in transplant recipients, Clinics, vol.70, issue.7, pp.515-538, 2015.

P. Ramanan and R. R. Razonable, Cytomegalovirus Infections in Solid Organ Transplantation: A Review, Infection & Chemotherapy, vol.45, issue.3, p.260, 2013.

P. Ljungman, M. Boeckh, H. H. Hirsch, F. Josephson, J. Lundgren et al., Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1. Snydman DR, éditeur, Clin Infect Dis. 1 janv, vol.64, issue.1, pp.87-91, 2017.

J. R. Freeman, The 'Indirect' Effects of Cytomegalovirus Infection, American Journal of Transplantation, vol.9, issue.11, pp.2453-2461, 2009.

C. N. Kotton, D. Kumar, A. M. Caliendo, S. Huprikar, S. Chou et al., The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ, Transplantation: Transplantation, vol.102, issue.6, pp.900-931, 2018.

A. Humar, Y. Lebranchu, F. Vincenti, E. A. Blumberg, J. D. Punch et al., The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients, American Journal of Transplantation. mai, vol.10, issue.5, pp.1228-1265, 2010.

O. Witzke, I. A. Hauser, M. Bartels, G. Wolf, H. Wolters et al., Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial, Transplantation. janv, vol.93, issue.1, pp.61-69, 2012.

J. Pascual, S. P. Berger, O. Witzke, H. Tedesco, S. Mulgaonkar et al., Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation, Journal of American Society of Nephrology, vol.29, issue.7, pp.1979-91, 2018.

S. G. Mallat, B. Y. Tanios, H. S. Itani, T. Lotfi, C. Mcmullan et al., CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials, Clinical Journal of American Society of Nephrology, vol.12, issue.8, pp.1321-1357, 2017.

G. Basso, C. R. Felipe, M. P. Cristelli, M. Siliano, J. Viana et al., The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial, Transpl Infect Dis, vol.20, issue.4, pp.1345-56, 2018.

V. Kliem, L. Fricke, T. Wollbrink, M. Burg, J. Radermacher et al., Improvement in Long-Term Renal Graft Survival due to CMV Prophylaxis with Oral Ganciclovir: Results of a Randomized Clinical Trial, American Journal of Transplantation, vol.8, issue.5, pp.975-983, 2008.

H. Kaminski, Complications infectieuses de la transplantation rénale. EMC Néphrologie, 2020.

N. S. Lurain and S. Chou, Antiviral Drug Resistance of Human Cytomegalovirus, Clinical Microbiology Reviews, vol.23, issue.4, pp.689-712, 2010.

A. Åsberg, A. Humar, H. Rollag, A. G. Jardine, H. Mouas et al., Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients, American Journal of Transplantation, vol.7, issue.9, pp.2106-2113, 2007.

A. Åsberg, A. Humar, A. G. Jardine, H. Rollag, M. D. Pescovitz et al., Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients, American Journal of Transplantation, vol.9, issue.5, pp.1205-1213, 2009.

G. Boivin, N. Goyette, H. Rollag, A. G. Jardine, M. D. Pescovitz et al., Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir, Antiviral Therapy, 2009.

A. Åsberg, A. G. Jardine, A. A. Bignamini, H. Rollag, M. D. Pescovitz et al., Effects of the Intensity of Immunosuppressive Therapy on Outcome of Treatment for CMV Disease in Organ Transplant Recipients, American Journal of Transplantation, vol.10, issue.8, pp.1881-1888, 2010.

J. A. Fishman and . Overview, Overview: Cytomegalovirus and the Herpesviruses in Transplantation, American Journal of Transplantation, vol.13, issue.s3, pp.1-8, 2013.

A. Åsberg, A. Humar, H. Rollag, A. G. Jardine, H. Mouas et al., Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients, American Journal of Transplantation, vol.7, issue.9, pp.2106-2113, 2007.

C. N. Kotton, D. Kumar, A. M. Caliendo, S. Huprikar, S. Chou et al., The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation, Transplantation, vol.102, issue.6, pp.900-931, 2018.

R. F. Chemaly, S. Chou, H. Einsele, P. Griffiths, R. Avery et al., Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials, Clinical Infectious Diseases, vol.68, issue.8, pp.1420-1426, 2018.

N. S. Lurain, S. M. Bhorade, K. J. Pursell, R. K. Avery, V. V. Yeldandi et al., Analysis and Characterization of Antiviral Drug?Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients, The Journal of Infectious Diseases, vol.186, issue.6, pp.760-768, 2002.

N. S. Lurain, S. M. Bhorade, K. J. Pursell, R. K. Avery, V. V. Yeldandi et al., Analysis and Characterization of Antiviral Drug?Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients, The Journal of Infectious Diseases, vol.186, issue.6, pp.760-768, 2002.

S. Hantz, S. Cotin, E. Borst, A. Couvreux, A. Salmier et al., Novel DNA polymerase mutations conferring cytomegalovirus resistance: Input of BAC-recombinant phenotyping and 3D model, Antiviral Research, vol.98, issue.1, pp.130-134, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01101111

T. Wreghitt, Cytomegalovirus infections in heart and heart-lung transplant recipients, Journal of Antimicrobial Chemotherapy, vol.23, issue.suppl E, pp.49-60, 1989.

G. Boivin, N. Goyette, H. Rollag, A. G. Jardine, M. D. Pescovitz et al.,

, Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir, Antiviral Therapy, 2009.

L. Couzi, S. Helou, T. Bachelet, K. Moreau, S. Martin et al., High Incidence of Anticytomegalovirus Drug Resistance Among D+R? Kidney Transplant Recipients Receiving Preemptive Therapy: Preemptive Therapy and Drug-Resistant CMV, American Journal of Transplantation, vol.12, issue.1, pp.202-211, 2012.

A. P. Limaye, G. Raghu, D. M. Koelle, J. Ferrenberg, M. Huang et al., High Incidence of Ganciclovir-Resistant Cytomegalovirus Infection among Lung Transplant Recipients Receiving Preemptive Therapy, Journal of Infectious Disease, vol.185, issue.1, pp.20-27, 2002.

N. S. Lurain and S. Chou, Antiviral Drug Resistance of Human Cytomegalovirus, Clinical Microbiology Reviews, vol.23, issue.4, pp.689-712, 2010.

. Cunha-bang-c-da, N. Kirkby, M. Sønderholm, S. S. Sørensen, H. Sengeløv et al., The Time Course of Development and Impact From Viral Resistance Against Ganciclovir in Cytomegalovirus Infection: Resistance Against Ganciclovir in CMV, American Journal of Transplantation, vol.13, issue.2, pp.458-66, 2013.

C. E. Fisher, J. L. Knudsen, E. D. Lease, K. R. Jerome, R. M. Rakita et al., Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients, Clinical Infectious Diseases, vol.65, issue.1, pp.57-63, 2017.

V. C. Emery and P. D. Griffiths, Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy, Proceedings of the National Academy of Sciences, vol.97, issue.14, pp.8039-8083, 2000.

G. Boivin, N. Goyette, M. Farhan, J. Ives, and R. Elston, Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis, Journal of Clinical Virology, vol.53, issue.3, pp.208-221, 2012.

R. K. Avery, R. Arav-boger, K. A. Marr, E. Kraus, S. Shoham et al., Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection: Transplantation, vol.100, pp.74-80, 2016.

A. Åsberg, A. Humar, A. G. Jardine, H. Rollag, M. D. Pescovitz et al., Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients, American Journal of Transplantation, vol.9, issue.5, pp.1205-1218, 2009.

I. Garrigue, S. Boucher, L. Couzi, A. Caumont, C. Dromer et al.,

, Whole blood real-time quantitative PCR for cytomegalovirus infection follow-up in transplant recipients, Journal of Clinical Virology, vol.36, issue.1, pp.72-77, 2006.

I. Garrigue, A. Doussau, J. Asselineau, H. Bricout, L. Couzi et al., Prediction of Cytomegalovirus (CMV) Plasma Load from Evaluation of CMV Whole-Blood Load in Samples from Renal Transplant Recipients, Journal of Clinical Microbiology, vol.46, issue.2, pp.493-501, 2008.

S. Chou, Approach to drug-resistant cytomegalovirus in transplant recipients: Current Opinion in Infectious Diseases, vol.28, pp.293-302, 2015.

P. Ljungman, M. Boeckh, H. H. Hirsch, F. Josephson, J. Lundgren et al., Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1. Snydman DR, éditeur, Clin Infect Dis, vol.64, issue.1, pp.87-91, 2017.

H. Kaminski, L. Couzi, I. Garrigue, J. Moreau, J. Déchanet-merville et al., Easier Control of Late-Onset Cytomegalovirus Disease Following Universal Prophylaxis Through an Early Antiviral Immune Response in Donor-Positive, Recipient-Negative Kidney Transplants, Am J Transplant, vol.16, issue.8, pp.2384-94, 2016.

Y. Natori, A. Humar, S. Husain, C. Rotstein, E. Renner et al., Recurrence of CMV Infection and the Effect of, Prolonged Antivirals in Organ Transplant Recipients: Transplantation, vol.101, issue.6, pp.1449-54, 2017.

H. Kaminski, I. Garrigue, L. Couzi, B. Taton, T. Bachelet et al., Surveillance of ?? T Cells Predicts Cytomegalovirus Infection Resolution in Kidney Transplants, Journal of American Society of Nephrology, vol.27, issue.2, pp.637-682, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01288893

D. Kumar, M. Mian, L. Singer, and A. Humar, An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation, Am J Transplant, vol.17, issue.9, pp.2468-73, 2017.

C. Martín-gandul, P. Pérez-romero, P. Blanco-lobo, O. J. Benmarzouk-hidalgo, M. Sánchez et al., Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy, Transpl Int, vol.27, issue.10, pp.1060-1068, 2014.

B. J. Gardiner, N. E. Nierenberg, J. K. Chow, R. Ruthazer, D. M. Kent et al.,

, Absolute Lymphocyte Count: A Predictor of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients, Clinical Infectious Diseases, vol.67, issue.9, pp.1395-402, 2018.

A. J. Eid, S. K. Arthurs, P. J. Deziel, M. P. Wilhelm, and R. R. Razonable, Clinical Predictors of Relapse after Treatment of Primary Gastrointestinal Cytomegalovirus Disease in Solid Organ Transplant Recipients: Predictors of Relapse of GI CMV Disease after SOT, American Journal of Transplantation, vol.10, issue.1, pp.157-61, 2010.

I. Helanterä, I. Lautenschlager, and P. Koskinen, The risk of cytomegalovirus recurrence after kidney transplantation: Recurrent CMV after kidney transplantation, Transplant International, vol.24, issue.12, pp.1170-1178, 2011.

B. J. Gardiner, J. K. Chow, L. L. Price, N. E. Nierenberg, D. M. Kent et al., Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients, Clinical Infectious Diseases, vol.65, issue.12, pp.109-165, 2000.

, Day 21 ciclosporin blood concentration (ng/ml, median, vol.140, pp.110-170

, Baseline Lymphocyte count (G/l, median, IQR)

, Abbreviations: Antibody Mediated Rejection (ABMR

, Antithymocyte Globulin (ATG

, Cytomegalovirus (CMV

, Donor (D)

, estimated Glomerular Filtration Rate (eGFR)

, T Cell Mediation Rejection (TCMR)

, Multivariate analysis was performed for all covariates in case of a p-value<0.25 observed in the univariate analysis (in bold). We decided, for clarity, to show only significant factors in multivariate analysis

, Serment d'Hippocrate

, Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions

, J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité

, Même sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l'humanité

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je donnerai mes soins à l'indigent et à quiconque me les demandera

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admis dans l'intimité des personnes, je tairai les secrets qui me seront confiés

, Reçu à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira

, Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission

, Je n'entreprendrai rien qui dépasse mes compétences

, Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses, que je sois déshonoré et méprisé si j'y manque. » Characteristics and time course of CMV infections leading to